We, Integrated ATTR-CM Partnership on AI Cardiac Technology (hereinafter referred to as “the Consortium”) aim to advance the medical field and create social value through collaboration among diverse stakeholders from industry and academia with varying perspectives. To ensure that participating members avoid conflicts of interest while promoting collaborative efforts of significant public interest, we have established the following engagement policy.

1. Pursuit of Goals

The Consortium will contribute to the achievement of early diagnosis of Cardiac Amyloidosis, including the utilization of AI, with each participating member acting in accordance with their respective articles of incorporation and the Consortium’s objectives.

2. Transparency of Activities

The Consortium and its participating members will maintain a high level of transparency in all activities through regular reporting and information sharing.

3. Neutrality in Management and Decision Making

The Consortium will be operated in a neutral manner, without favoring the interest of any specific member.

4. Appropriate Use of Data and Deliverables

The Consortium will use the data, deliverables, and other materials created and managed by the Consortium appropriately, in accordance with established procedures and management guidelines.

5. Consideration for the public interest and future of participation

When private companies or organizations with highly promising technologies participate, the Consortium will establish cooperative relationships on an equal footing. This will enable the Consortium to promote both the public interest and innovation.

• Website Term of Use
• Privacy Policy
• Consortium Engagement Policy